|
WO2020248065A1
|
|
Unsaturated heterocycloalkyl and heteroaromatic acyl hydrazone linkers, methods and uses thereof
|
|
WO2020248064A1
|
|
Nicotinamide phosphoribosyltransferase (nampt) inhibitor-conjugates and uses thereof
|
|
WO2020232548A1
|
|
Pan-cancer transcriptional signature
|
|
WO2020176983A1
|
|
Amide-based proteolysis modulators of b-rapidly accelerated fibrosarcoma (braf) and associated uses
|
|
US2020331921A1
|
|
Inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof
|
|
EP3728231A1
|
|
Novel deuterated compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders
|
|
EP3728267A1
|
|
Tricyclic inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof
|
|
US2021106694A1
|
|
Heterocyclic acyl hydrazone linkers, methods and uses thereof
|
|
CA3086362A1
|
|
Novel quinolone compounds as inhibitors of the bcl6 btb domain protein-protein interaction and/or as bcl6 degraders
|
|
CA3084092A1
|
|
Acyl hydrazone linkers, methods and uses thereof
|
|
WO2018170578A1
|
|
Cancer risk based on tumour clonality
|
|
WO2018049506A1
|
|
Mirna prostate cancer marker
|
|
US2019112672A1
|
|
Mitochondrial dna prostate cancer marker and related systems and methods
|
|
US2019055608A1
|
|
Multi-modal prostate cancer marker
|
|
US2019010553A1
|
|
Gene Signature of Residual Risk Following Endocrine Treatment in Early Breast Cancer
|
|
US2018282819A1
|
|
Targeting the Histone Pathway to Detect and Overcome Anthracyclin Resistance
|
